John Marioni elected to EMBO Membership
Senior Group Leader, Dr John Marioni, has been elected a member of the European Molecular Biology Organisation (EMBO) in recognition of his high-quality life science research.
Marioni is one of 64 life scientists that have been elected to EMBO membership this year, joining a community of more than 1,800 leading life scientists.
EMBO Members are actively involved in the organisation. They serve on EMBO Council, Committees, and Advisory Editorial Boards of EMBO Press journals, evaluate applications for EMBO funding, and mentor early-career scientists. Collectively, they can influence the direction of the life sciences in Europe and beyond.
“I am delighted to welcome the new members into our organisation and look forward to working with them,” says EMBO Director Maria Leptin. “An election to the EMBO Membership recognises outstanding achievements in the life sciences. The new members will provide expertise and guidance that will help EMBO to further strengthen its initiatives.”
New members are nominated and elected by the existing EMBO Membership; it is not possible to apply to become a member. One election is held each year. The new EMBO Members will be formally welcomed at the annual EMBO Members’ Meeting between 27 and 29 October 2021.
Related News
See all news-
Dr Guiping Wang appointed as a Junior Group Leader
18th May 2026
Dr Guiping Wang joins the Cancer Research UK Cambridge Institute as a Junior Group Leader, starting in September 2026.
Find out more -
Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research
14th May 2026
The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies.
Find out more -
Prof Sir Steve Jackson receives the 2026 Galen Medal in Therapeutics
14th May 2026
This award comes in recognition of his transformational work on the mechanisms of DNA repair, cell survival and the DNA-damage response (DDR), as well as for the development of the cancer-targeting drug Olaparib.
Find out more